https://orcid.org/0000-0002-6350-9758
References
- Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22(2):99–103.
- Mocroft A, Lundgren JD, Ross M, et al. Data collection on adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23–32–e32.
- Casado JL, del Rey JM, Bañón S, et al. Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients. J Acquir Immune Defic Syndr. 2016;72(4):416–422.
- Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89(5):513–519.
- Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55(1):78–81.
- Yoshino M, Yagura H, Kushida H, et al. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation. J Infect Chemother. 2012;18(2):169–174.
- Jose S, Hamzah L, Campbell LJ, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis. 2014;210(3):363–373.
- Bonjoch A, Echeverría P, Perez-Alvare N, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res. 2012;96(1):65–69.
- Thailand National Guidelines on HIV/AIDS Treatment and Prevention. 2017. http://www.thaiaidssociety.org/images/PDF/hiv_thai_guideline_2560.pdf
- Payne RB. Renal tubular reabsorption of phosphate, (TmP/GFR): indications and interpretation. Ann Clin Biochem. 1998;35(2):201–206.
- Henry JB, Richard AM, Matthew RP. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Philadelphia, PA: Elsevier/Saunders; 2011.
- Manual of Laboratory Investigations. https://chulalongkornhospital.go.th/kcmh/wp-content/uploads/2017/12/008-22-3-60.pdf. Accessed May 30, 2022.
- Nishijima T, Mutoh Y, Kawasaki Y, et al. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. AIDS. 2018;32(2):179–188.
- EACS guidelines v.11.0. Available at www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
- Wahbeh AM, Ewais MH, Elsharif ME. Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria. Saudi J Kidney Dis Transpl. 2009;20(3):443–447.
- Gökçe Ç, Gökçe Ö, Baydinç C, et al. Use of Random Urine Samples to Estimate Total Urinary Calcium and Phosphate Excretion. Arch Intern Med. 1991;151(8):1587–1588.
- Choi ST, Moon SJ, Kang EJ. Random urinary uric acid/creatinine ratio is useful in the estimation of 24-hour urine uric acid excretion in patients with gout [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).